MEOX2 and lung carcinoma: Additional Kaplan-Maier survival curve analyses of lung adenocarcinoma patients representing 84% (76/90) of the total INCAN lung cancer patient cohort indicated poorer overall survival (statistically significant at p≤0.005) in lung adenocarcinoma patients with higher MEOX2 and GLI-1 protein co-expression levels (p=0.079 and p=0.002, respectively) (Figure 9B).